top of page

CELGENE STOCK ANALYSIS: Fighting Cancer

  • Writer: Ishfaaq Peerally
    Ishfaaq Peerally
  • Apr 26, 2019
  • 1 min read

Celgene is the third largest biotech company in the world after Amgen and Gilead Sciences

Celgene is focused on oncology, that is, the treatment of cancers.

42% of revenue of Celgene comes from Revlimid which is used by patients with multiple myeloma.

Bristol-Myers Squib (BMS) is going to acquire Celgene in the coming months and there is the opportunity to make an arbitrage trade.

 
 
 

Comentários


Contact



ishfaaq@ishfaaqpeerally.com

  • X
  • Instagram
  • YouTube

© 2016 - 2025 All Rights Reserved

Ishfaaq Peerally

bottom of page